论文部分内容阅读
目的观察托吡酯治疗不同类型癫疒间的长期疗效及安全性。方法采用开放性试验的方法,给予115例不同类型癫疒间患者托吡酯单药或添加治疗,6个月后进行疗效评定,1年和2年时计算控制率和托吡酯保留率,记录不良反应。结果(1)6个月时总有效率单药治疗组为83.9%,添加治疗组为66.1%,对各型癫疒间均有一定疗效,各组间发作控制率和总有效率比较差异无显著性;(2)稳定期儿童组有效剂量为(105.72±48.28)mg/d,成人组为(176.36±62.81)mg/d;(3)控制率1年为40.0%,2年为28.7%;保留率1年为67.8%,2年为46.1%;(4)34例(29.6%)出现不良反应,为轻、中度的中枢神经系统症状以及厌食和体质量减轻。结论托吡酯是较好的广谱抗癫疒间药物,长期应用仍有较好的疗效和安全性。
Objective To observe the long-term efficacy and safety of topiramate in the treatment of different types of epilepsy. Methods One hundred and fifteen patients with different types of epilepsy were given topiramate monotherapy or addition therapy. The efficacy was evaluated after six months. The rates of control and topiramate retention were calculated at one year and two years, and the adverse reactions were recorded. Results (1) At 6 months, the total effective rate was 83.9% in the monotherapy group and 66.1% in the treatment group. There was a certain curative effect in all types of epilepsy. There was no significant difference between the control and total effective rates (3) The control rate was 40.0% in 1 year and 28.7% in 2 years in stable group (105.72 ± 48.28) mg / d, and in adult group (176.36 ± 62.81) mg / ; The retention rate was 67.8% for 1 year and 46.1% for 2 years; (4) 34 patients (29.6%) had adverse reactions, mild to moderate central nervous system symptoms, and anorexia and weight loss. Conclusion Topiramate is a good broad-spectrum anti-epileptic drug, long-term use still has good efficacy and safety.